These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16086639)

  • 21. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 22. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
    Fukutake K
    Semin Thromb Hemost; 2000; 26(1):29-32. PubMed ID: 10805278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A therapeutic alternative for haemophiliacs with inhibitors.
    Schulman S
    Acta Paediatr; 1992; 81(6-7):564-5. PubMed ID: 1392376
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of high dose factor VIIa in hemophilia patients.
    Hedner U
    Adv Exp Med Biol; 2001; 489():75-88. PubMed ID: 11554593
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgery and survival in birth cohorts with severe haemophilia and differences in access to replacement therapy: The Malmö experience.
    Osooli M; Steen Carlsson K; Astermark J; Berntorp E
    Haemophilia; 2017 Sep; 23(5):e403-e408. PubMed ID: 28758324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
    Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
    Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemophilia in Iran.
    Dorgalaleh A; Dadashizadeh G; Bamedi T
    Hematology; 2016 Jun; 21(5):300-10. PubMed ID: 26914731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
    Pabinger-Fasching I; Négrier C
    Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
    [No Abstract]   [Full Text] [Related]  

  • 32. Hemophilia and prophylaxis.
    Ljung R
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of joint bleeding in hemophilia.
    Simpson ML; Valentino LA
    Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
    Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
    Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.
    Urasinski T; Stasyshyn O; Andreeva T; Rusen L; Perina FG; Oh MS; Chapman M; Pavlova BG; Valenta-Singer B; Abbuehl BE
    Haemophilia; 2015 Mar; 21(2):196-203. PubMed ID: 25495591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
    Greenmyer JR; Grindeland CJ; Kobrinsky NL
    Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.